Use of Dexamethasone in the clinical management of patients with COVID-19 requiring respiratory intervention ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) USE OF DEXAMETHASONE IN THE TREATMENT OF PATIENTS WITH COVID-19 REQUIRING RESPIRATORY INTERVENTION To ensure the equal distribution of information which may possibly be price sensitive, Aspen has noted the preliminary results of a drug trial using dexamethasone in the treatment of patients with COVID-19 requiring respiratory intervention and the related media coverage. It is confirmed that Aspen owns rights to this product and distributes both injectables and/or tablets containing dexamethasone in a number of countries. Aspen markets an injectable dexamethasone in South Africa, which is manufactured locally by a third party. Durban 17 June 2020 Sponsor Investec Bank Limited Date: 17-06-2020 10:42:00 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.